| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
16,510,000 |
| Market
Cap: |
1.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0449 - $0.5548 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sunshine Biopharma is a pharmaceutical company. Co.'s proprietary drug development activities are focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. Co.'s Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. has licensing agreements with a primary pharmaceutical company for four prescription generic drugs for the treatment of breast cancer, prostate cancer and enlarged prostate. These four generic products are Anastrozole, Letrozole, Bicalutamide, and Finasteride. Co. develops Essential 9™, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
120,000 |
120,000 |
150,000 |
| Total Buy Value |
$0 |
$12,000 |
$12,000 |
$34,905 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Slilaty Steve N. |
Chief Executive Officer |
• • – |
2016-04-22 |
4 |
A |
$0.01 |
$84,000 |
D/D |
12,000,000 |
12,384,373 |
|
- |
|
| Sebaaly Camille |
CFO and Secretary |
• • – |
2016-04-22 |
4 |
A |
$0.01 |
$84,000 |
D/D |
12,000,000 |
12,234,373 |
|
- |
|
| Merzouki Abderrazzak |
Chief Operating Officer |
• • – |
2016-04-22 |
4 |
A |
$0.01 |
$84,000 |
D/D |
12,000,000 |
13,467,000 |
|
- |
|
| Slilaty Steve N. |
Chief Executive Officer |
• • – |
2016-04-12 |
4 |
B |
$0.20 |
$50,009 |
I/I |
253,082 |
30,570,776 |
2.66 |
- |
|
| Slilaty Steve N. |
Chief Executive Officer |
• • • |
2015-05-27 |
4 |
B |
$0.10 |
$50,000 |
D/D |
500,000 |
500,000 |
3.23 |
- |
|
| Merzouki Abderrazzak |
Chief Operating OfficerOfficer |
• • – |
2015-02-20 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
1,467,000 |
|
- |
|
| Merzouki Abderrazzak |
Chief Operating OfficerOfficer |
• • – |
2015-02-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,467,000 |
|
- |
|
| Slilaty Steve N. |
Chief Executive Officer |
• • • |
2015-01-09 |
4 |
A |
$0.02 |
$3,000 |
D/D |
150,000 |
384,373 |
|
- |
|
| Slilaty Steve N. |
Chief Executive Officer |
• • • |
2015-01-09 |
4 |
D |
$0.02 |
$24,000 |
I/I |
(1,200,000) |
30,317,694 |
|
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|
